-
MITSUBISHI TANABE PHARMA CORPORATION et al v. MACLEODS PHARMACEUTICALS, LTD. et al DC
- 1:17-cv-13130
- D.N.J.
- Judge: Renee Marie Bumb
+1
- Filed: 12/15/2017
- Closed: 04/08/2020
- Latest Docket Entry: 01/28/2021
- PACER
- Docket updated daily
5
Plaintiffs
2
Defendants
2
Accused
Products
2
Patents-in-Suit
846
Days in
Litigation
-
MITSUBISHI TANABE PHARMA CORPORATION et al v. MACLEODS PHARMACEUTICALS, LTD. et al DC
- 1:17-cv-13130
- D.N.J.
- Judge: Renee Marie Bumb
+1
- Filed: 12/15/2017
- Closed: 04/08/2020
- Latest Docket Entry: 01/28/2021
- PACER
- Docket updated daily
Cause of Action
Infringement
Assigned Judge
Outcome Summary
- Patent Information
-
Validity & Enforceability
-
Infringement
Hetero Labs Limited
- 2 Details
| Accused Product | Patent # | Claim # | Outcome |
|---|---|---|---|
| Generic versions of JPI’s 100 mg and 300 mg INVOKANA® drug product | US 7,943,582 B2 | All Asserted Claims |
Infringement
Entry 13
|
| Generic versions of JPI’s 100 mg and 300 mg INVOKANA® drug product | US 8,513,202 B2 | All Asserted Claims |
Infringement
Entry 13
|
Hetero Labs Limited Unit V
- 2 Details
| Accused Product | Patent # | Claim # | Outcome |
|---|---|---|---|
| Generic versions of JPI’s 100 mg and 300 mg INVOKANA® drug product | US 7,943,582 B2 | All Asserted Claims |
Infringement
Entry 13
|
| Generic versions of JPI’s 100 mg and 300 mg INVOKANA® drug product | US 8,513,202 B2 | All Asserted Claims |
Infringement
Entry 13
|
Hetero USA Incorporated
- 2 Details
| Accused Product | Patent # | Claim # | Outcome |
|---|---|---|---|
| Generic versions of JPI’s 100 mg and 300 mg INVOKANA® drug product | US 7,943,582 B2 | All Asserted Claims |
Infringement
Entry 13
|
| Generic versions of JPI’s 100 mg and 300 mg INVOKANA® drug product | US 8,513,202 B2 | All Asserted Claims |
Infringement
Entry 13
|
Laurus Labs Limited
- 2 Details
| Accused Product | Patent # | Claim # | Outcome |
|---|---|---|---|
| Generic versions of 100 mg and 300 mg INVOKANA drug product | US 7,943,582 B2 | All Asserted Claims |
Infringement
Entry 17
|
| Generic versions of 100 mg and 300 mg INVOKANA drug product | US 8,513,202 B2 | All Asserted Claims |
Infringement
Entry 17
|
Lupin Limited
- 2 Details
| Accused Product | Patent # | Claim # | Outcome |
|---|---|---|---|
| generic version of canagliflozin 150 mg / 1 gm tabletsgeneric version of canagliflozin 150 mg / 500 mg tabletsgeneric version of canagliflozin 50 mg / 1 gm tabletsgeneric version of canagliflozin 50 mg / 500 mg tablets | US 7,943,582 B2 | All Asserted Claims |
Infringement
Entry 19
|
| generic version of canagliflozin 150 mg / 1 gm tabletsgeneric version of canagliflozin 150 mg / 500 mg tabletsgeneric version of canagliflozin 50 mg / 1 gm tabletsgeneric version of canagliflozin 50 mg / 500 mg tablets | US 8,513,202 B2 | All Asserted Claims |
Infringement
Entry 19
|
Lupin Pharmaceuticals Incorporated
- 2 Details
| Accused Product | Patent # | Claim # | Outcome |
|---|---|---|---|
| generic version of canagliflozin 150 mg / 1 gm tabletsgeneric version of canagliflozin 150 mg / 500 mg tabletsgeneric version of canagliflozin 50 mg / 1 gm tabletsgeneric version of canagliflozin 50 mg / 500 mg tablets | US 7,943,582 B2 | All Asserted Claims |
Infringement
Entry 19
|
| generic version of canagliflozin 150 mg / 1 gm tabletsgeneric version of canagliflozin 150 mg / 500 mg tabletsgeneric version of canagliflozin 50 mg / 1 gm tabletsgeneric version of canagliflozin 50 mg / 500 mg tablets | US 8,513,202 B2 | All Asserted Claims |
Infringement
Entry 19
|
Macleods Pharmaceuticals Limited
- 2 Details
| Accused Product | Patent # | Claim # | Outcome |
|---|---|---|---|
| INVOKANA tablet | US 7,943,582 B2 | All Asserted Claims |
Infringement
Entry 16
|
| INVOKANA tablet | US 8,513,202 B2 | All Asserted Claims |
Infringement
Entry 16
|
Macleods Pharma USA Incorporated
- 2 Details
| Accused Product | Patent # | Claim # | Outcome |
|---|---|---|---|
| INVOKANA tablet | US 7,943,582 B2 | All Asserted Claims |
Infringement
Entry 16
|
| INVOKANA tablet | US 8,513,202 B2 | All Asserted Claims |
Infringement
Entry 16
|
